Clinical Trial Search

Primary: Number of Participants With Adequacy of Suppression of Estradiol (E2) as Assessed by Estradiol Level Below 40 pg/mL — 6; 7; 5; 12 Participants

Primary: The Number of Participants With an Objective Tumor Response Rate — 3 participants

Primary: Participant Acceptability of the Interventions — 1; 0 Participants

Primary: Biomarker FGFR1 (ISH/SISH) Score (Part A) — 0.93; 0.07; 0.579; 0.42 gene copy number

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…

Primary: Number (%) of Participants With an Hb Response by Week 17 — 19; 24; 21; 23 Participants

Primary: Overall Response (OR) — 0; 3; 3; 1 Participants

Primary: Participants That Developed Severity Score 3 or Higher Oral Chronic Graft Versus Host Disease (GVHD). — 7; 4 Participants

Primary: Objective Response Rate (ORR) — 30; 30 percentage of participants

Primary: Objective Response Rate (ORR) Based on Lugano Classification Criteria — 50.0; 33.3; 57.1; 58.3 percentage of participants

Primary: Objective Response Rate (ORR) — 8.3; 39.0; 64.5; 71.4 percentage of participants

Primary: Objective Response Rate With Parsaclisib Based on Lugano Classification Response Criteria — 65.2; 77.7 percentage of participants

Primary: Progression-free Survival (PFS) — 2.5 months

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 5 Participants

Primary: Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 — 46; 45; 47; 47…